Date: 2016-01-19
Type of information: Grant
Company: Inovio Pharmaceuticals (USA - PA)
Investors: U.S. Army’s Small Business Innovation Research (SBIR) program
Amount: $500,000
Funding type: grant
Planned used: The grant will be used to further advance the development of Inovio’s next generation delivery device capable of simultaneously administering multiple vaccines via a skin-surface, needle-free electroporation delivery. The primary goal of this U.S. Army-funded effort is to further develop a device that would facilitate rapid vaccination of U.S. troops stationed around the world against multiple infectious diseases and protect civilian populations from pandemic threats. The new needle-free device could be used to deliver Inovio’s portfolio of biodefense and commercial infectious disease vaccines including those for MERS, Ebola, HIV, influenza, and RSV.
Others: * On January 19, 2016, Inovio Pharmaceuticals announced it has been selected to receive a $500,000 grant from the U.S. Army’s Small Business Innovation Research (SBIR) program to further advance the development of Inovio’s next generation delivery device capable of simultaneously administering multiple vaccines via a skin-surface, needle-free electroporation delivery. Initial testing of a prototype design has already yielded excellent antigen expression and immunogenicity from the dermal tissue being accessed using this novel non-invasive electroporation delivery concept.
Therapeutic area: Technology - Services - Infectious diseases
